drugset / Trial / NCT03843151

A Study in Healthy Men to Test How Itraconazole Influences the Amount of BI 1358894 in the Blood

NCT03843151

Phase 1 Completed 16 enrolled Boehringer Ingelheim
NaSequentialOpen-labelTreatment

Summary

The main objective of this trial is to investigate the relative bioavailability of BI 1358894 in plasma when given as oral single dose together with multiple oral doses of itraconazole (Test, T) as compared to when given alone as oral single dose (Reference, R).

Timeline

Start
2019-03-19
Primary completion
2019-06-03
Completion
2019-06-03

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 1358894 Small molecule 10 mg Oral
Subject Itraconazole Small molecule 200 mg Oral

Indications

No indication recorded.